Discounted Cash Flow
Akari Therapeutics Plc. ADR
—
—
Cash flow predictability 70/100 (stable) —
FCF YoY std dev 27%,
net income 50% (full history)
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | — | $-24.5m | $-33.4m | — | — |
| 2017 | — | $-47.9m (-95.1%) | $-42.8m (-28.2%) | — | — |
| 2018 | — | $-22.3m (53.5%) | $-30.5m (28.6%) | — | — |
| 2019 | — | $-23.1m (-3.9%) | $-17.5m (42.8%) | — | $-0.01 |
| 2020 | — | $-23.1m (0.1%) | — | — | $-0.01 (0.0%) |
| 2021 | — | $-23.6m (-2.0%) | — | — | $0.00 (100.0%) |
| 2022 | — | $-24.0m (-1.9%) | — | — | $0.00 |
| 2023 | — | $-13.5m (43.6%) | $-22.2m | — | $0.00 |
| 2024 | — | $-26.8m (-97.8%) | $-17.0m (23.6%) | — | $0.00 |
| 2025 | — | $-23.4m (12.6%) | $-14.3m (15.8%) | — | $0.00 |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
SEC filings report in GBP. Values above are converted to USD for comparison with the US-listed share price.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Net debt deduction: —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.